OLEMA PHARMACEUTICALS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $601.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $300.00K, a 4.17% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $301.00K, a 4.88% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $301.00K, a 4.88% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $300.00K, a 4.17% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.18M, a 2.26% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.15M, a 11.33% decline from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.30M, a 0.31% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.30M, a 6.29% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $601.00K 10-Q · filed 2026-08-10 | $902.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $301.00K 10-Q · filed 2026-05-12 | $602.00K derived: sum of 2 quarters · filed 2026-05-12 | $902.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.19M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $301.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $601.00K derived: sum of 2 quarters · filed 2026-03-16 | $889.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.18M 10-K · filed 2026-03-16 |
| 2025-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $588.00K derived: sum of 2 quarters · filed 2026-08-10 | $875.00K 10-Q · filed 2025-11-10 | $1.16M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $288.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $575.00K 10-Q · filed 2026-08-10 | $862.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $287.00K 10-Q · filed 2026-05-12 | $574.00K derived: sum of 2 quarters · filed 2026-05-12 | $862.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.15M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $575.00K derived: sum of 2 quarters · filed 2026-03-16 | $862.00K derived: sum of 3 quarters · filed 2026-03-16 | $1.15M 10-K · filed 2026-03-16 |
| 2024-09-30 | $288.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $575.00K derived: sum of 2 quarters · filed 2025-11-10 | $863.00K 10-Q · filed 2025-11-10 | $1.19M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $287.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $575.00K 10-Q · filed 2025-08-11 | $899.00K derived: sum of 3 quarters · filed 2025-08-11 | $1.22M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $288.00K 10-Q · filed 2025-05-13 | $612.00K derived: sum of 2 quarters · filed 2025-05-13 | $932.00K derived: sum of 3 quarters · filed 2025-05-13 | $1.26M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $324.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $644.00K derived: sum of 2 quarters · filed 2025-03-18 | $970.00K derived: sum of 3 quarters · filed 2025-03-18 | $1.30M 10-K · filed 2025-03-18 |
| 2023-09-30 | $320.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $646.00K derived: sum of 2 quarters · filed 2024-11-12 | $973.00K 10-Q · filed 2024-11-12 | $1.30M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $326.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $653.00K 10-Q · filed 2024-08-06 | $979.00K derived: sum of 3 quarters · filed 2024-08-06 | $1.31M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $327.00K 10-Q · filed 2024-05-08 | $653.00K derived: sum of 2 quarters · filed 2024-05-08 | $980.00K derived: sum of 3 quarters · filed 2024-05-08 | $1.30M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $326.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $653.00K derived: sum of 2 quarters · filed 2024-03-11 | $978.00K derived: sum of 3 quarters · filed 2024-03-11 | $1.30M 10-K · filed 2024-03-11 |
| 2022-09-30 | $327.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $652.00K derived: sum of 2 quarters · filed 2023-11-07 | $975.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $325.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $648.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $323.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $1.22M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |